GCC's ~140,000 Saudi Arabia SCD patients depend on a 25-year-old generic after both novel disease-modifiers hit regulatory trouble since 2023.
GCC carries an estimated 200,000-250,000 sickle cell disease patients, with Saudi Arabia alone accounting for roughly 140,000, among the highest national disease burdens outside sub-Saharan Africa. Carrier frequency reaches 6-7% in Saudi Arabia's Eastern Province and 10-15% in Bahrain and Oman. National premarital screening programmes operate in Saudi Arabia, the UAE, Qatar, and Bahrain, and are measurably reshaping epidemiology: carrier-carrier marriages are declining 15-20% annually in Saudi Arabia. Hydroxyurea, generic and available since 1998, remains the region's only disease-modifying therapy with a stable market position, prescribed to an estimated 35-40% of eligible patients, a higher rate than the US's 25-30% attributed to closer government health-system monitoring. Adherence tracking remains inconsistent outside specialist centres such as KFSH&RC and KAMC.
Both novel disease-modifying agents that reached GCC registration have since encountered regulatory setbacks. Crizanlizumab (Adakveo), SFDA-registered in 2021 on the strength of a 45.3% vaso-occlusive-crisis reduction in SUSTAIN, was withdrawn from the EU market in 2023 after its confirmatory trial failed, leaving its GCC formulary position under MOH review and prescribing uncertain. Voxelotor (Oxbryta), registered on HOPE trial data showing a 1.5 g/dL haemoglobin increase, was voluntarily withdrawn by the FDA in 2024 for the same reason, and most GCC centres are now transitioning patients off the drug rather than starting new prescriptions. Gene therapies Casgevy and Lyfgenia, FDA- and EMA-approved in December 2023, are not yet SFDA- or MOHAP-registered as of mid-2024, with registration expected 18-24 months post-FDA. No GCC centre currently holds the qualified cell-therapy infrastructure to deliver them, though KFSH&RC and SKMC are building CAR-T and gene-therapy capability that could accommodate SCD gene therapy by 2025-2026.
Approved sickle cell disease agents — GCC, 2024
| Drug (Brand / INN) | Mechanism | Company | GCC Registration | Key Trial Result | GCC Access Status |
|---|---|---|---|---|---|
| Hydroxyurea (generic) | Oral HbF inducer | Multiple generic manufacturers | Available since 1998; dominant SoC | VOC −44% (MSH) | Prescribed to ~35-40% of eligible patients; better GCC adherence monitoring than US |
| Adakveo (crizanlizumab) | Anti-P-selectin mAb IV | Novartis | SFDA registered 2021; withdrawn from EU 2023 | VOC reduction 45.3% vs placebo (SUSTAIN) | MOH review ongoing post-EU withdrawal; prescribing uncertainty |
| Oxbryta (voxelotor) | HbS polymerisation inhibitor, oral | Pfizer (GBT) | FDA voluntary withdrawal 2024 | Hgb +1.5 g/dL (HOPE) | Most GCC centres transitioning patients off; not accepting new prescriptions |
Sources: SFDA registration records; MOH review documentation; MSH trial (hydroxyurea); SUSTAIN trial (crizanlizumab); HOPE trial (voxelotor); Al-Qurashi MM et al. Eur J Haematol 2010; NPHC Saudi SCD programme 2022; Al-Salem AH et al. Saudi Med J 2019; KFSH&RC cell therapy programme 2023.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- MOH review status for crizanlizumab
- GCC centre-level prescribing response to both withdrawals
- patient-transition protocols in use
Delivers
- SFDA registration-timeline modelling for gene therapies
- KFSH&RC and SKMC cell-therapy infrastructure build-out
- first-mover centre readiness assessment
Delivers
- Premarital screening programme mechanics and coverage by country
- carrier-frequency data (Eastern Province, Bahrain, Oman)
- demand-trajectory implications for disease-modifying and curative therapies
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- Why Saudi Arabia alone carries an estimated 140,000 of the GCC's 200,000-250,000 sickle cell disease patients, among the highest national burdens outside sub-Saharan Africa.
- How national premarital screening programmes in Saudi Arabia, the UAE, Qatar, and Bahrain are cutting carrier-carrier marriages by 15-20% annually in Saudi Arabia.
- Why hydroxyurea, generic since 1998, still reaches 35-40% of eligible GCC patients against just 25-30% in the US, attributed to closer government health-system monitoring.
- Crizanlizumab's 45.3% vaso-occlusive-crisis reduction in SUSTAIN against voxelotor's 1.5 g/dL haemoglobin increase in HOPE, the data behind each drug's original SFDA registration.
- Why crizanlizumab's 2023 EU withdrawal, after its confirmatory trial failed, has left its GCC formulary position under active MOH review.
- How most GCC centres are already transitioning patients off voxelotor rather than starting new prescriptions, following its 2024 FDA voluntary withdrawal.
- Why Casgevy and Lyfgenia, FDA- and EMA-approved in December 2023, still face an 18-24 month SFDA/MOHAP registration timeline with no local application yet as of mid-2024.
- How KFSH&RC and SKMC are building the CAR-T and gene-therapy infrastructure that could make them the first GCC centres able to deliver SCD gene therapy by 2025-2026.
- Why hydroxyurea remains the only disease-modifying SCD therapy with a stable, established GCC access pathway, while crizanlizumab's formulary status sits in MOH review.
- How adherence tracking for disease-modifying therapy remains inconsistent outside specialist centres such as KFSH&RC and KAMC, even where access exists.
- The concentration of specialist SCD adherence-tracking and hydroxyurea monitoring at KFSH&RC and KAMC, versus inconsistent tracking elsewhere in the region.
- How KFSH&RC and SKMC are positioning as the region's first cell-therapy-capable centres, making them likely gatekeepers for future gene-therapy referrals.
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (FDA, SFDA, MOH, ClinicalTrials.gov), peer-reviewed literature, and live payer/formulary policy documentation — not secondary summaries. Findings are independently verified before inclusion.
Sickle Cell Disease GCC CI sources: SFDA registration records, NPHC Saudi SCD programme 2022, MSH trial (hydroxyurea), SUSTAIN trial (crizanlizumab), HOPE trial (voxelotor), Al-Qurashi MM et al. Eur J Haematol 2010, Al-Salem AH et al. Saudi Med J 2019, and KFSH&RC cell therapy programme 2023 reporting on gene-therapy infrastructure readiness.
- Drug registration and withdrawal status verified against SFDA records and public regulatory announcements (EU withdrawal 2023, FDA voluntary withdrawal 2024)
- Clinical trial results verified against published primary sources (MSH, SUSTAIN, HOPE)
- GCC prevalence and carrier-frequency figures verified against NPHC Saudi SCD programme reporting and published epidemiology (Al-Qurashi MM et al.)
- Gene-therapy infrastructure and registration-timeline status verified against KFSH&RC cell therapy programme reporting and SFDA registration tracking data
Frequently asked questions
Commission this brief
AXLRx delivers Sickle Cell Disease competitive intelligence for the GCC market, built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.